I-Mab (IMAB) announced positive interim data from its U.S. phase 2/3 study of plonmarlimab for the treatment of cytokine release syndrome or CRS in patients with severe COVID-19.
The Interim analysis showed positive preliminary results for maintaining patients without mechanical ventilation and reducing the mortality rate, with shortened time to recovery and hospitalization duration.
The company noted that a reduction in key pro-inflammatory cytokines and chemokines critically involved in cytokine release syndrome was observed in patients treated with plonmarlimab compared to placebo.
According to the company, plonmarlimab treatment was well tolerated with no significant safety concerns in patients with severe COVID-19.
The company plans to continue advancing the study in the U.S. and begins to explore other CRS-related opportunities.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.